Drugs / GOLOCDACIMAB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03654313 | Sep 2018 → Jul 2020 | atherosclerosis | MedImmune LLC | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT05912218 | Nov 2023 → Sep 2025 overdue | peripheral arterial disease, type 2 diabetes mellitus | National Heart Centre Singapore | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04610892 | Nov 2020 → Nov 2023 | coronary artery disorder | AstraZeneca | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GOLOCDACIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095363 ↗ |
| Known as | MEDI6570 | “MEDI6570 affects lower limb microvascular perfusion and atheroma inflammation and progression” NCT05912218 ↗ |
| Modality | Monoclonal antibody | “MEDI6570, a high-affinity monoclonal blocking antibody to LOX-1.” PMID 36688371 ↗ Jan 2023 |
| Route | Subcutaneous | “Monthly Subcutaneous administration.” NCT04610892 ↗ |